Artiva Biotherapeutics
Artiva Biotherapeutics Seeks $116M in Second IPO Attempt for Cell Therapy Development
Artiva Biotherapeutics, IPO, cell therapy, AlloNK, systemic lupus erythematosus, autoimmune diseases
Actionable Insights Powered by AI
Artiva Biotherapeutics, IPO, cell therapy, AlloNK, systemic lupus erythematosus, autoimmune diseases